Furthermore, inhibition of ILT4 promoted the efficacy of PD-L1 inhibitors and abrogated TAMs- and T cell-involved immunosuppression in NSCLC cells with EGFR activation. The gene discussed is LILRB2; the disease is non-small cell lung carcinoma.